Myasthenia Gravis Pipeline Summary

DelveInsight’s, “Myasthenia Gravis - Pipeline Insight, 2026” report provides comprehensive insights about 28+ companies and 30+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Myasthenia Gravis: Understanding

Myasthenia Gravis: Overview

Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction characterized by fluctuating skeletal muscle weakness that worsens with activity and improves with rest. The disease most commonly affects the ocular, bulbar, respiratory, and limb muscles. In most patients, autoantibodies directed against postsynaptic proteins impair neuromuscular transmission, resulting in fatigable muscle weakness.

MG develops in genetically susceptible individuals due to an autoimmune response against proteins at the neuromuscular junction. The most common target is the nicotinic acetylcholine receptor (AChR), while other pathogenic antibodies target muscle-specific kinase (MuSK) or lipoprotein receptor-related protein 4 (LRP4). Approximately 10% of patients have an associated thymoma, and disease onset or exacerbation may be triggered by infections, surgery, immunization, medications, or other physiological stressor.

The pathogenesis of MG involves autoantibody-mediated disruption of neuromuscular transmission. In AChR-positive MG, IgG1 and IgG3 antibodies activate the complement cascade, leading to membrane attack complex (MAC) formation and destruction of the postsynaptic membrane. Autoantibodies also block acetylcholine receptor function and accelerate receptor internalization, reducing the number of functional receptors available for neuromuscular signaling. The resulting impairment of synaptic transmission causes muscle fatigability and weakness.

The diagnosis of MG is based on clinical presentation together with serological and electrophysiological testing. Detection of AChR, MuSK, or LRP4 antibodies supports the diagnosis, while repetitive nerve stimulation and single-fiber electromyography demonstrate impaired neuromuscular transmission. Imaging of the thymus using CT or MRI is recommended to identify thymic hyperplasia or thymoma. Bedside tests and assessment of response to acetylcholinesterase inhibitors may also aid diagnosis.

Treatment of MG focuses on improving neuromuscular transmission and suppressing the autoimmune response. Acetylcholinesterase inhibitors, particularly pyridostigmine, provide symptomatic relief, while corticosteroids and steroid-sparing immunosuppressants are used for long-term disease control. Rapidly acting therapies such as intravenous immunoglobulin (IVIG) or plasma exchange are indicated for myasthenic crisis or severe exacerbations. Thymectomy is recommended in selected patients, especially those with thymoma, and targeted biologic therapies are increasingly used in patients with refractory disease.

"Myasthenia Gravis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myasthenia Gravis pipeline landscape is provided which includes the disease overview and Myasthenia Gravis treatment guidelines. The assessment part of the report embraces, in depth Myasthenia Gravis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myasthenia Gravis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Myasthenia Gravis R&D. The therapies under development are focused on novel approaches to treat/improve Myasthenia Gravis.

Myasthenia Gravis Emerging Drugs Chapters

This segment of the Myasthenia Gravis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Myasthenia Gravis Emerging Drugs

• Claseprubart (DNTH103): Dianthus Therapeutics

Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, infrequently dosed, self-administered injection. Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways. As the classical pathway plays a significant role in disease pathology, claseprubart has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Myasthenia Gravis.

• IM-101: ImmunAbs Inc.

IM-101 is an investigational humanized anti-complement C5 monoclonal antibody developed by ImmunAbs Inc. for the treatment of generalized myasthenia gravis (gMG) and ocular myasthenia gravis (oMG). Administered by intravenous infusion, IM-101 is designed to selectively bind complement component C5 and inhibit its cleavage into C5a and C5b, thereby preventing formation of the membrane attack complex (C5b-9) responsible for complement-mediated damage at the neuromuscular junction. By preserving acetylcholine receptor integrity and improving neuromuscular transmission, the therapy aims to reduce muscle weakness and disease symptoms. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Myasthenia Gravis.

• Rapcabtagene autoleucel (YTB323): Novartis AG

Rapcabtagene autoleucel (YTB323) is an investigational autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy developed by Novartis for the treatment of generalized myasthenia gravis (gMG). Manufactured using the proprietary T-Charge™ platform, YTB323 is designed to preserve naïve and stem cell memory T cells, enabling rapid manufacturing while enhancing T-cell expansion and persistence. By targeting and eliminating CD19-expressing B cells, the therapy aims to reduce the production of pathogenic autoantibodies that drive myasthenia gravis. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Myasthenia Gravis.

• Zolacabtagene autoleucel: Bristol-Myers Squibb

Zolacabtagene autoleucel is an investigational autologous CD19-targeted NEX-T CAR T-cell therapy which is manufactured using the company's NEX-T™ cell therapy platform, which is designed to enhance T-cell fitness, expansion, and persistence while enabling a streamlined manufacturing process. Following a single infusion, zola-cel selectively targets and eliminates CD19-expressing B cells, including autoreactive B cells that produce pathogenic autoantibodies implicated in MG, with the goal of achieving deep B-cell depletion, immune system reset, and durable disease remission. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Myasthenia Gravis.

Further product details are provided in the report……..

Myasthenia Gravis: Therapeutic Assessment

This segment of the report provides insights about the different Myasthenia Gravis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Myasthenia Gravis

There are approx. 28+ key companies which are developing the therapies Myasthenia Gravis. The companies which have their Myasthenia Gravis drug candidates in the most advanced stage, i.e. Phase III include, Dianthus Therapeutics and others.

• Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Myasthenia Gravis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myasthenia Gravis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myasthenia Gravis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myasthenia Gravis drugs.

Myasthenia Gravis Report Insights

• Myasthenia Gravis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Myasthenia Gravis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Myasthenia Gravis drugs?
• How many Myasthenia Gravis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myasthenia Gravis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myasthenia Gravis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Myasthenia Gravis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Dianthus Therapeutics
• ImmunAbs Inc.
• Bristol-Myers Squibb
• Novartis AG
• Candid Therapeutics
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Nanjing IASO Biotechnology Co., Ltd.
• Rallybio
• Roivant Science(Immunovant Sciences GmbH)
• HanAll Biopharma
• TG Therapeutics, Inc.
• Precision Biosciences
• Candid Therapeutics

Key Products

• Claseprubart (DNTH103)
• IM-101
• Zolacabtagene autoleucel
• Rapcabtagene autoleucel (YTB323)
• Cizutamig
• SYS6020
• Eque-cel (CT103A)
• RLYB116
• Imeroprubart(IMVT-1402)
• Azercabtagene zapreleucel
• Cizutamig